Pear Therapeutics and Prescryptive Health Announce Formulary Coverage for Prescription Digital Therapeutics reSET® & reSET-O® for the Treatment of Substance and Opioid Use Disorders
By
Staff
2 seconds ago
Prescryptive Health, a health intelligence platform focused on improving the prescription drug market and the pharmacy experience, teams with Pear to make innovative prescription digital therapeutics (PDTs) accessible to its members in recovery.
Prescryptive Health will offer and administer Pear’s reSET® and reSET-O® through its digital platform as a covered standard pharmacy benefit for people with substance use disorder or opioid use disorder.
BOSTON & SAN FRANCISCO & REDMOND, Wash.–(BUSINESS WIRE)–Pear Therapeutics, Inc. and Prescryptive Health today announced that Prescryptive, the first health intelligence platform, will offer and administer benefit coverage for reSET® and reSET-O®, the first two prescription digital therapeutics (PDTs) to receive authoriza
Company adds a leading national Integrated Delivery Network (IDN) as a strategic investor.
The financing supports Pear’s continued efforts to expand patient access for its portfolio of Prescription Digital Therapeutics (PDTs), including reSET®, reSET-O® and Somryst® treating addiction and insomnia conditions, respectively.
BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc., (“Pear” or the “Company”) today announced the second closing of its Series D financing. The second closing included a leading national Integrated Delivery Network (IDN) as a new strategic investor. The national IDN is investing $20 million, bringing the total Series D investment to $100 million.
“Pear is pleased to add one of America’s leading health care providers and health plans to our distinguished list of investors as we continue to expand patient access to our FDA-authorized digital therapeutics,” said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics. �
Pear Therapeutics Announces Publication of Economic Analysis Showing Cost-Effectiveness of reSET-O® in Treating Opioid Use Disorder digitalmedianet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitalmedianet.com Daily Mail and Mail on Sunday newspapers.
News Category Global Banking & Finance Reviews
Groups Recover Together Teams with Pear Therapeutics to Provide People in Recovery Access to Innovative Treatment
Groups Recover Together Teams with Pear Therapeutics to Provide People in Recovery Access to Innovative Treatment Opioid use disorder (OUD) is often an isolating experience and with COVID-19-related social distancing, fostering recovery is challenging. Recover Together, Inc. (Groups), a leading outpatient treatment provider serving individuals with OUD across eight states, and Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced a combined effort to treat OUD patients by providing them with Pears innovative technology as well as Groups innovative approach to treatment.
Pear Therapeutics Announces Publication of Economic Analysis Assessing the Cost-Effectiveness of reSET-O® in Treating Opioid Use Disorder (OUD)
By
Staff
4 months ago
reSET-O® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for patients with opioid use disorder (OUD).
New economic analysis showed reSET-O to be cost-effective compared to treatment-as-usual alone over 12 weeks, and to have economic dominance when contingency management (CM) was included as part of treatment as usual.
BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc., today announced publication of a new economic analysis describing the cost-effectiveness of reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD). The analysis, “